Dermacyd PH_DETINLYN Sweet Flower (Lactic Acid) - Safety
NCT ID: NCT00785148
Last Updated: 2009-03-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
31 participants
INTERVENTIONAL
2008-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Dermacyd PH_DETINBACK (Lactic Acid) Sweet Flower - Safety.
NCT00785850
Dermacyd PH_DETINLYN Tangerine Mix (Lactic Acid) - Safety.
NCT00785642
Dermacyd PH_DETINBACK (Lactic Acid) Sweet Flower - Compatibility
NCT00785681
Dermacyd Femina Pocket BR (Lactic Acid)- Acceptability.
NCT00794612
Dermacyd PH_DETINBACK Tangerine Mix (Lactic Acid) - Safety.
NCT00783939
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Dermacyd PH\_DETINLYN Sweet Flower (Lactic Acid)
Dermacyd PH_DETINLYN Sweet Flower (Lactic Acid)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dermacyd PH_DETINLYN Sweet Flower (Lactic Acid)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Use of cosmetic product of the same category
Exclusion Criteria
* Use of Anti-inflammatory, immunosuppression or anti-histaminic drugs
* Atopic antecedent or allergic to cosmetic product
* Active cutaneous disease in the evaluation area
* Diseases which cause immunology decrease, such as diabetes and HIV
* Endocrinal pathologies
* Intense solar exposure 15 days before the evaluation
* Treatment until four months before the selection
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
10 Years
20 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sanofi
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
sanofi-aventis
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jaderson Lima
Role: STUDY_DIRECTOR
Sanofi
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sanofi-Aventis Administrative Office
São Paulo, , Brazil
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LACAC_L_04298
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.